PMID- 38384647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240224
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 16
IP  - 1
DP  - 2024 Jan
TI  - Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on 
      Targeted Therapy.
PG  - e52737
LID - 10.7759/cureus.52737 [doi]
LID - e52737
AB  - The malfunctioning of human leukocyte antigen (HLA) class I antigens has a 
      substantial negative impact on the effectiveness of leukemia treatment, 
      particularly in the development of immunotherapies that rely on T-cell 
      activation. HLA-G, a molecule that suppresses the immune response, plays a role 
      in repressing the activation and proliferation of T cells, natural killer cells, 
      and antigen-presenting cells. The expression of HLA-G is associated with various 
      pathological conditions. Tumor cells exploit the immune evasion capabilities of 
      HLA, allowing them to evade detection and elimination by the immune system. 
      Understanding and modifying the HLA molecules is crucial for the advancement of 
      innovative immunotherapies targeting chronic lymphocytic leukemia. Numerous 
      mechanisms have been investigated to elucidate how HLA facilitates tumor evasion 
      in patients with chronic lymphocytic leukemia and other malignancies. These 
      mechanisms include inhibiting immune cell cytolysis, altering cytokine production 
      levels, promoting immune cell programmed cell death, and impairing chemotaxis. 
      This review provides a comprehensive overview of immune evasion mediated by HLA 
      and its implications for targeted therapy.
CI  - Copyright (c) 2024, Andreescu et al.
FAU - Andreescu, Mihaela
AU  - Andreescu M
AD  - Faculty of Medicine, Titu Maiorescu University, Bucharest, ROU.
AD  - Hematology, Colentina Clinical Hospital, Bucharest, ROU.
FAU - Andreescu, Bogdan
AU  - Andreescu B
AD  - Plastic Surgery, Colentina Clinical Hospital, Bucharest, ROU.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240122
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10880808
OTO - NOTNLM
OT  - hla
OT  - immune evasion
OT  - kir
OT  - natural killer cells
OT  - targeted therapies
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/02/22 06:43
MHDA- 2024/02/22 06:44
PMCR- 2024/01/22
CRDT- 2024/02/22 03:52
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/02/22 06:44 [medline]
PHST- 2024/02/22 06:43 [pubmed]
PHST- 2024/02/22 03:52 [entrez]
PHST- 2024/01/22 00:00 [pmc-release]
AID - 10.7759/cureus.52737 [doi]
PST - epublish
SO  - Cureus. 2024 Jan 22;16(1):e52737. doi: 10.7759/cureus.52737. eCollection 2024 
      Jan.